These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 27116727)

  • 21. Pathologic and imaging correlates of cognitive deficits in multiple sclerosis: changing the paradigm of diagnosis and prognosis.
    Shi J; Baxter LC; Kuniyoshi SM
    Cogn Behav Neurol; 2014 Mar; 27(1):1-7. PubMed ID: 24674960
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Cognitive impairment in multiple sclerosis].
    Karlińska I; Selmaj K
    Neurol Neurochir Pol; 2005; 39(2):125-33. PubMed ID: 15871058
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Deficits in Social Cognition: An Unveiled Signature of Multiple Sclerosis.
    Chalah MA; Ayache SS
    J Int Neuropsychol Soc; 2017 Mar; 23(3):266-286. PubMed ID: 28069095
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Subclinical MRI disease activity influences cognitive performance in MS patients.
    Damasceno A; Damasceno BP; Cendes F
    Mult Scler Relat Disord; 2015 Mar; 4(2):137-43. PubMed ID: 25787189
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The association between intra- and juxta-cortical pathology and cognitive impairment in multiple sclerosis by quantitative T
    Louapre C; Govindarajan ST; Giannì C; Madigan N; Nielsen AS; Sloane JA; Kinkel RP; Mainero C
    Neuroimage Clin; 2016; 12():879-886. PubMed ID: 27872810
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacological and Non-pharmacological Therapies of Cognitive Impairment in Multiple Sclerosis.
    Miller E; Morel A; Redlicka J; Miller I; Saluk J
    Curr Neuropharmacol; 2018; 16(4):475-483. PubMed ID: 29119933
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Correlation between demyelinating lesions and executive function decline in a sample of Mexican patients with multiple sclerosis].
    Aldrete Cortez VR; Duriez-Sotelo E; Carrillo-Mora P; Pérez-Zuno JA
    Neurologia; 2013 Sep; 28(7):394-9. PubMed ID: 23260448
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Determinants of Cognitive Impairment in Patients with Multiple Sclerosis with and without Atrophy.
    Eijlers AJC; Meijer KA; van Geest Q; Geurts JJG; Schoonheim MM
    Radiology; 2018 Aug; 288(2):544-551. PubMed ID: 29786489
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cognitive dysfunction in multiple sclerosis: a review of recent developments.
    Bobholz JA; Rao SM
    Curr Opin Neurol; 2003 Jun; 16(3):283-8. PubMed ID: 12858063
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Brain structural profile of multiple system atrophy patients with cognitive impairment.
    Fiorenzato E; Weis L; Seppi K; Onofrj M; Cortelli P; Zanigni S; Tonon C; Kaufmann H; Shepherd TM; Poewe W; Krismer F; Wenning G; Antonini A; Biundo R;
    J Neural Transm (Vienna); 2017 Mar; 124(3):293-302. PubMed ID: 27778099
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cognitive reserve moderates the impact of subcortical gray matter atrophy on neuropsychological status in multiple sclerosis.
    Modica CM; Bergsland N; Dwyer MG; Ramasamy DP; Carl E; Zivadinov R; Benedict RH
    Mult Scler; 2016 Jan; 22(1):36-42. PubMed ID: 25921038
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anatomical and functional correlates of cognitive deficit in multiple sclerosis.
    Pozzilli C; Gasperini C; Anzini A; Grasso MG; Ristori G; Fieschi C
    J Neurol Sci; 1993 Apr; 115 Suppl():S55-8. PubMed ID: 8340794
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neuropsychology of multiple sclerosis: a critical review.
    Rao SM
    J Clin Exp Neuropsychol; 1986 Oct; 8(5):503-42. PubMed ID: 3805250
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multiple sclerosis and cognition: synaptic failure and network dysfunction.
    Di Filippo M; Portaccio E; Mancini A; Calabresi P
    Nat Rev Neurosci; 2018 Oct; 19(10):599-609. PubMed ID: 30158590
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cognitive reserve in multiple sclerosis.
    Sumowski JF; Leavitt VM
    Mult Scler; 2013 Aug; 19(9):1122-7. PubMed ID: 23897894
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Grey matter lesions in MS: from histology to clinical implications.
    Calabrese M; Favaretto A; Martini V; Gallo P
    Prion; 2013; 7(1):20-7. PubMed ID: 23093801
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cognition in multiple sclerosis.
    Langdon DW
    Curr Opin Neurol; 2011 Jun; 24(3):244-9. PubMed ID: 21519256
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MRI markers of destructive pathology in multiple sclerosis-related cognitive dysfunction.
    Rovaris M; Comi G; Filippi M
    J Neurol Sci; 2006 Jun; 245(1-2):111-6. PubMed ID: 16626748
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cognitive impairment in multiple sclerosis.
    Jongen PJ; Ter Horst AT; Brands AM
    Minerva Med; 2012 Apr; 103(2):73-96. PubMed ID: 22513513
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anticholinesterasics in the treatment of cognitive impairment in multiple sclerosis.
    Porcel J; Montalban X
    J Neurol Sci; 2006 Jun; 245(1-2):177-81. PubMed ID: 16674980
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.